Ionut Bebu1, Barbara H Braffett2, Rodica Pop-Busui3, Trevor J Orchard4, David M Nathan5, John M Lachin2. 1. The Biostatistics Center, The George Washington University, 6110 Executive Boulevard, Rockville, MD, 20852, USA. ibebu@bsc.gwu.edu. 2. The Biostatistics Center, The George Washington University, 6110 Executive Boulevard, Rockville, MD, 20852, USA. 3. Department of Internal Medicine, Division of Metabolism, Endocrinology and Diabetes, University of Michigan, Ann Arbor, MI, USA. 4. Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA. 5. Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Abstract
AIMS/HYPOTHESIS: Chronic hyperglycaemia, as measured by HbA1c levels, is a major risk factor for atherosclerosis and cardiovascular disease (CVD) in type 1 diabetes. Our aim was to describe the degree to which the effect of HbA1c on the risk of CVD is mediated by its effect on traditional risk factors over time, and how these mediation pathways change over time. METHODS: The DCCT and its observational follow-up study, the Epidemiology of Diabetes Interventions and Complications (EDIC), followed 1441 participants for a mean of 27 years, with periodic measurement of HbA1c and risk factors over time. We assessed the proportion of the HbA1c effect on risk of CVD that was mediated through its effects on systolic BP (SBP), pulse rate, triacylglycerols and LDL-cholesterol (LDLc) levels, and how the proportion mediated changed over time. RESULTS: The association of HbA1c with CVD outcomes was stable over time, while that of traditional risk factors (SBP, pulse rate, triacylglycerols and LDLc) increased. At 10 years of follow-up, the effect of HbA1c on 10 year CVD risk was minimally mediated by SBP (2.7%), increasing to 26% at 20 years. Likewise, from 10 year follow-up to 20 year follow-up, the proportion of HbA1c effect mediated through pulse rate increased from 6.3% to 29.3%, through triacylglycerols from 2.2% to 22.4%, and through LDLc from 9.2% to 30.7%. CONCLUSIONS/ INTERPRETATION: As participants age, the predictive association of mean HbA1c on subsequent CVD events is increasingly mediated by its effect on standard risk factors. Thus, management of traditional non-glycaemic CVD risk factors may have increasing benefits in an ageing type 1 diabetes population with longstanding hyperglycaemia. TRIAL REGISTRATION: ClinicalTrials.gov NCT00360893 and NCT00360815.
RCT Entities:
AIMS/HYPOTHESIS: Chronic hyperglycaemia, as measured by HbA1c levels, is a major risk factor for atherosclerosis and cardiovascular disease (CVD) in type 1 diabetes. Our aim was to describe the degree to which the effect of HbA1c on the risk of CVD is mediated by its effect on traditional risk factors over time, and how these mediation pathways change over time. METHODS: The DCCT and its observational follow-up study, the Epidemiology of Diabetes Interventions and Complications (EDIC), followed 1441 participants for a mean of 27 years, with periodic measurement of HbA1c and risk factors over time. We assessed the proportion of the HbA1c effect on risk of CVD that was mediated through its effects on systolic BP (SBP), pulse rate, triacylglycerols and LDL-cholesterol (LDLc) levels, and how the proportion mediated changed over time. RESULTS: The association of HbA1c with CVD outcomes was stable over time, while that of traditional risk factors (SBP, pulse rate, triacylglycerols and LDLc) increased. At 10 years of follow-up, the effect of HbA1c on 10 year CVD risk was minimally mediated by SBP (2.7%), increasing to 26% at 20 years. Likewise, from 10 year follow-up to 20 year follow-up, the proportion of HbA1c effect mediated through pulse rate increased from 6.3% to 29.3%, through triacylglycerols from 2.2% to 22.4%, and through LDLc from 9.2% to 30.7%. CONCLUSIONS/ INTERPRETATION: As participants age, the predictive association of mean HbA1c on subsequent CVD events is increasingly mediated by its effect on standard risk factors. Thus, management of traditional non-glycaemic CVD risk factors may have increasing benefits in an ageing type 1 diabetes population with longstanding hyperglycaemia. TRIAL REGISTRATION: ClinicalTrials.gov NCT00360893 and NCT00360815.
Entities:
Keywords:
Area under the curve; Cardiovascular disease; Mediation proportion; Type 1 diabetes
Authors: David M Nathan; Patricia A Cleary; Jye-Yu C Backlund; Saul M Genuth; John M Lachin; Trevor J Orchard; Philip Raskin; Bernard Zinman Journal: N Engl J Med Date: 2005-12-22 Impact factor: 91.245
Authors: Ian H de Boer; Tessa C Rue; Patricia A Cleary; John M Lachin; Mark E Molitch; Michael W Steffes; Wanjie Sun; Bernard Zinman; John D Brunzell; Neil H White; Ronald P Danis; Matthew D Davis; Dean Hainsworth; Larry D Hubbard; David M Nathan Journal: Arch Intern Med Date: 2011-03-14
Authors: Ralph B D'Agostino; Ramachandran S Vasan; Michael J Pencina; Philip A Wolf; Mark Cobain; Joseph M Massaro; William B Kannel Journal: Circulation Date: 2008-01-22 Impact factor: 29.690
Authors: Andrew D Paterson; Brandy N Rutledge; Patricia A Cleary; John M Lachin; Richard S Crow Journal: Diabetes Care Date: 2007-04-27 Impact factor: 19.112
Authors: Ivana Semova; Amy E Levenson; Joanna Krawczyk; Kevin Bullock; Kathryn A Williams; R Paul Wadwa; Amy S Shah; Philip R Khoury; Thomas R Kimball; Elaine M Urbina; Sarah D de Ferranti; Franziska K Bishop; David M Maahs; Lawrence M Dolan; Clary B Clish; Sudha B Biddinger Journal: J Clin Lipidol Date: 2019-09-25 Impact factor: 4.766
Authors: Jenny E Kanter; Baohai Shao; Farah Kramer; Shelley Barnhart; Masami Shimizu-Albergine; Tomas Vaisar; Mark J Graham; Rosanne M Crooke; Clarence R Manuel; Rebecca A Haeusler; Daniel Mar; Karol Bomsztyk; John E Hokanson; Gregory L Kinney; Janet K Snell-Bergeon; Jay W Heinecke; Karin E Bornfeldt Journal: J Clin Invest Date: 2019-07-11 Impact factor: 14.808
Authors: Arpita Basu; Ionut Bebu; Alicia J Jenkins; Julie A Stoner; Ying Zhang; Richard L Klein; Maria F Lopes-Virella; W Timothy Garvey; Matthew J Budoff; Petar Alaupovic; Timothy J Lyons Journal: J Lipid Res Date: 2019-06-15 Impact factor: 5.922
Authors: Viral N Shah; Ryan Bailey; Mengdi Wu; Nicole C Foster; Rodica Pop-Busui; Michelle Katz; Jill Crandall; Fida Bacha; Kristen Nadeau; Ingrid Libman; Paul Hiers; Kara Mizokami-Stout; Linda A DiMeglio; Jennifer Sherr; Richard Pratley; Shivani Agarwal; Janet Snell-Bergeon; Eda Cengiz; Sarit Polsky; Sanjeev N Mehta Journal: J Clin Endocrinol Metab Date: 2020-05-01 Impact factor: 5.958